Abstract
Brain glucose hypometabolism has been observed in Alzheimer’s disease (AD) patients, and is detected with 18F radiolabelled glucose, using positron emission tomography. A pathological hallmark of AD is deposition of brain β- amyloid plaques that may influence cerebral glucose metabolism. The five times familial AD (5XFAD) mouse is a model of brain amyloidosis exhibiting AD-like phenotypes. This study examines brain β-amyloid plaque deposition and 18FDG uptake, to search for an early biomarker distinguishing 5XFAD from wild-type mice. Thus, brain 18FDG uptake and plaque deposition was studied in these mice at age 2, 5 and 13 months. The 5XFAD mice demonstrated significantly reduced brain 18FDG uptake at 13 months relative to wild-type controls but not in younger mice, despite substantial β- amyloid plaque deposition. However, by comparing the ratio of uptake values for glucose in different regions in the same brain, 5XFAD mice could be distinguished from controls at age 2 months. This method of measuring altered glucose metabolism may represent an early biomarker for the progression of amyloid deposition in the brain. We conclude that brain 18FDG uptake can be a sensitive biomarker for early detection of abnormal metabolism in the 5XFAD mouse when alternative relative uptake values are utilized.
Keywords: Alzheimer's disease, β-amyloid, computed tomography, glucose metabolism, magnetic resonance imaging, positron emission tomography, standardized uptake value, Tg6799.
Current Alzheimer Research
Title:Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse
Volume: 11 Issue: 5
Author(s): I.R. Macdonald, D.R. DeBay, G.A. Reid, T.P. O’Leary, C.T. Jollymore, G. Mawko, S. Burrell, E. Martin, C.V. Bowen, R.E. Brown and S. Darvesh
Affiliation:
Keywords: Alzheimer's disease, β-amyloid, computed tomography, glucose metabolism, magnetic resonance imaging, positron emission tomography, standardized uptake value, Tg6799.
Abstract: Brain glucose hypometabolism has been observed in Alzheimer’s disease (AD) patients, and is detected with 18F radiolabelled glucose, using positron emission tomography. A pathological hallmark of AD is deposition of brain β- amyloid plaques that may influence cerebral glucose metabolism. The five times familial AD (5XFAD) mouse is a model of brain amyloidosis exhibiting AD-like phenotypes. This study examines brain β-amyloid plaque deposition and 18FDG uptake, to search for an early biomarker distinguishing 5XFAD from wild-type mice. Thus, brain 18FDG uptake and plaque deposition was studied in these mice at age 2, 5 and 13 months. The 5XFAD mice demonstrated significantly reduced brain 18FDG uptake at 13 months relative to wild-type controls but not in younger mice, despite substantial β- amyloid plaque deposition. However, by comparing the ratio of uptake values for glucose in different regions in the same brain, 5XFAD mice could be distinguished from controls at age 2 months. This method of measuring altered glucose metabolism may represent an early biomarker for the progression of amyloid deposition in the brain. We conclude that brain 18FDG uptake can be a sensitive biomarker for early detection of abnormal metabolism in the 5XFAD mouse when alternative relative uptake values are utilized.
Export Options
About this article
Cite this article as:
Macdonald I.R., DeBay D.R., Reid G.A., O’Leary T.P., Jollymore C.T., Mawko G., Burrell S., Martin E., Bowen C.V., Brown R.E. and Darvesh S., Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse, Current Alzheimer Research 2014; 11 (5) . https://dx.doi.org/10.2174/1567205011666140505111354
DOI https://dx.doi.org/10.2174/1567205011666140505111354 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Cognitive Speed of Processing Training Among Older Adults with Psychometrically- Defined Mild Cognitive Impairment
Current Alzheimer Research Selective Agonists and Antagonists for Kainate Receptors
Mini-Reviews in Medicinal Chemistry Osteoporosis Entwined with Cardiovascular Disease: The Implication of Osteoprotegerin and the Example of Statins
Current Medicinal Chemistry Lipids as Key Players in Alzheimer Disease - Alterations in Metabolism and Genetics
Current Alzheimer Research Metabotropic Glutamate Receptors Modulate Periaqueductal Grey Descending Analgesic System
Central Nervous System Agents in Medicinal Chemistry New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Family-Based Therapy for Adolescent Anorexia: The Nuts and Bolts of Empowering Families to Renourish Their Children
Adolescent Psychiatry Orchestrating HIV Neutralization by Secondary Immune Response- Mediated Induction of RF Antibodies
Current Immunology Reviews (Discontinued) Editorial
Central Nervous System Agents in Medicinal Chemistry Inhibition of β-Amyloid Aggregation by Albiflorin, Aloeemodin and Neohesperidin and their Neuroprotective Effect on Primary Hippocampal Cells Against β-Amyloid Induced Toxicity
Current Alzheimer Research Evidence Based Psychosocial Practices and Recovery from Schizophrenia
Current Psychiatry Reviews Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimers Disease
Current Medicinal Chemistry Incorporation of Natural Renewable Components and Waste Byproducts to Benzoxazine Based High Performance Materials
Current Organic Chemistry Efficient and Green Synthetic Protocol for the Synthesis of Structurally Diverse Spiroheterocycles using GAAS as Catalytic Solvent
Current Organocatalysis PP2A and Alzheimer Disease
Current Alzheimer Research Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress
Current Pharmacogenomics and Personalized Medicine Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology